Cetuximab Solution for infusion

DRUG2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd.

Conditions

Advanced KRAS G12D Mutant Solid TumorsHead and Neck Squamous Cell Cancer

Phase 1

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Shanghai Junshi Bioscience Co., Ltd.Head and Neck Squamous Cell Cancer

Start: 2021-04-06End: 2023-11-30Target: 88Updated: 2022-12-19

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Active, not recruitingNCT06385678

Jiangsu HengRui Medicine Co., Ltd.Advanced KRAS G12D Mutant Solid Tumors

Start: 2024-07-05End: 2026-08-31Updated: 2025-09-19

Related Papers

678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial

Regular and Young Investigator Award Abstracts2023-10-31

Preliminary safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): A phase Ib/II clinical trial.

Journal of Clinical Oncology2022-06-012 citations